Following Bridge Biotherapeutics?
Get the free weekly contract digest
The latest new contracts, like Bridge Biotherapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Bridge Biotherapeutics and HitGen Initiate Research Collaboration for Cancer Therapeutics
Aug 22, 2024•almost 2 years ago
Contract Type
partnership
ChengduBiotechnologyBiopharmaDescription
Bridge Biotherapeutics and HitGen have entered into a joint research agreement to advance novel cancer therapeutics program. The collaboration aims to develop promising drug candidates for various types of cancer, building on the successful initial hit finding and identification work from HitGen's DNA-encoded library (DEL).
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months